Calcitonin: Physiology or fantasy?

Journal of Bone and Mineral Research

Volumn 28, Issue 5, 2013, Pages 973-979

  Davey, Rachel A ^a   Findlay, David M ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bone Turnover; Calcitonin; Calcitonin Receptor; Calcium Homeostasis

Indexed keywords

CALCITONIN; CALCITONIN RECEPTOR; CALCIUM;

BONE MINERAL; BONE TURNOVER; CALCIUM HOMEOSTASIS; HYPERCALCEMIA; LACTATION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; REVIEW; SIGNAL TRANSDUCTION; SKELETON;

CALCITONIN; HUMANS; RECEPTORS, CALCITONIN; SIGNAL TRANSDUCTION;

EID: 84876718523     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1869     Document Type: Review

References (76)

1. Sexton PM, Findlay DM, Martin TJ., Calcitonin. Curr Med Chem. 1999 Nov; 6 (11): 1067-93.
2. Findlay DM, Sexton PM., Calcitonin. Growth Factors. 2004 Dec; 22 (4): 217-24.
3. Findlay DM., Regulation of cell growth mediated by the calcitonin receptor. Cell Mol Biol. 2006; 52 (3): 3-8.
4. Sexton PM, Houssami S, Hilton JM, O'Keeffe LM, Center RJ, Gillespie MT, Darcy P, Findlay DM., Identification of brain isoforms of the rat calcitonin receptor. Mol Endocrinol. 1993 Jun; 7 (6): 815-21.
5. Moore EE, Kuestner RE, Stroop SD, Grant FJ, Matthewes SL, Brady CL, Sexton PM, Findlay DM., Functionally different isoforms of the human calcitonin receptor result from alternative splicing of the gene transcript. Mol Endocrinol. 1995 Aug; 9 (8): 959-68.
6. Udawela M, Christopoulos G, Tilakaratne N, Christopoulos A, Albiston A, Sexton PM., Distinct receptor activity-modifying protein domains differentially modulate interaction with calcitonin receptors. Mol Pharmacol. 2006 Jun; 69 (6): 1984-9.
7. Seck T, Baron R, Horne WC., The alternatively spliced deltae13 transcript of the rabbit calcitonin receptor dimerizes with the C1a isoform and inhibits its surface expression. J Biol Chem. 2003 Jun 20; 278 (25): 23085-93.
8. Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y, Hori M, Suda T., Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology. 1996 Nov; 137 (11): 4685-90.
9. Granholm S, Lundberg P, Lerner UH., Calcitonin inhibits osteoclast formation in mouse haematopoetic cells independently of transcriptional regulation by receptor activator of NF-{kappa}B and c-Fms. J Endocrinol. 2007 Dec; 195 (3): 415-27.
10. Samura A, Wada S, Suda S, Iitaka M, Katayama S., Calcitonin receptor regulation and responsiveness to calcitonin in human osteoclast-like cells prepared in vitro using receptor activator of nuclear factor-kappaB ligand and macrophage colony-stimulating factor. Endocrinology. 2000 Oct; 141 (10): 3774-82.
11. Zhang Z, Neff L, Bothwell AL, Baron R, Horne WC., Calcitonin induces dephosphorylation of Pyk2 and phosphorylation of focal adhesion kinase in osteoclasts. Bone. 2002 Sep; 31 (3): 359-65.
12. Raggatt LJ, Evdokiou A, Findlay DM., Sustained activation of Erk1/2 MAPK and cell growth suppression by the insert-negative, but not the insert-positive isoform of the human calcitonin receptor. J Endocrinol. 2000 Oct; 167 (1): 93-105.
13. Zhang Z, Baron R, Horne WC., Integrin engagement, the actin cytoskeleton, and c-Src are required for the calcitonin-induced tyrosine phosphorylation of paxillin and HEF1, but not for calcitonin-induced Erk1/2 phosphorylation. J Biol Chem. 2000 Nov 24; 275 (47): 37219-23.
14. Sexton PM, Poyner DR, Simms J, Christopoulos A, Hay DL., Modulating receptor function through RAMPs: can they represent drug targets in themselves ? Drug Discov Today. 2009 Apr; 14 (7-8): 413-9.
15. Martin TJ, Findlay DM, Sexton PM., Calcitonin. In:, DeGroot LJ, Jameson JL, editors. Endocrinology 5th edition. Philadelphia: Elsevier Saunders; 2006. p. 1419-33.
16. Foster GV., Calcitonin A review of experimental and clinical investigations. Postgrad Med J. 1968 May; 44 (511): 411-22.
17. Friedman J, Raisz LG., Thyrocalcitonin: inhibitor of bone resorption in tissue culture. Science. 1965 Dec 10; 150 (3702): 1465-7.
18. Chambers TJ, Athanasou NA, Fuller K., Effect of parathyroid hormone and calcitonin on the cytoplasmic spreading of isolated osteoclasts. J Endocrinol. 1984 Sep; 102 (3): 281-6.
19. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ., Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest. 1986 Aug; 78 (2): 355-60.
20. Del Fattore A, Teti A, Rucci N., Osteoclast receptors and signaling. Arch Biochem Biophys. 2008 May 15; 473 (2): 147-60.
21. Moonga BS, Moss DW, Patchell A, Zaidi M., Intracellular regulation of enzyme secretion from rat osteoclasts and evidence for a functional role in bone resorption. J Physiol. 1990 Oct; 429: 29-45.
22. Mancini L, Moradi-Bidhendi N, Brandi ML, Perretti M, MacIntyre I., Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. Biochem Biophys Res Commun. 2000 Dec 20; 279 (2): 391-7.
23. Cochran M, Peacock M, Sachs G, Nordin BE., Renal effects of calcitonin. Br Med J. 1970 Jan 17; 1 (689): 135-7.
24. Bijvoet OL, van der Sluys Veer J, Jansen AP., Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia. Lancet. 1968 Apr 27; 1 (7548): 876-81.
25. Zhong Y, Armbrecht HJ, Christakos S., Calcitonin, a regulator of the 25-hydroxyvitamin D3 1alpha-hydroxylase gene. J Biol Chem. 2009 Apr 24; 284 (17): 11059-69.
26. Shinki T, Ueno Y, DeLuca HF, Suda T., Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1alpha-hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci U S A. 1999 Jul 6; 96 (14): 8253-8.
27. Jaeger P, Jones W, Clemens TL, Hayslett JP., Evidence that calcitonin stimulates 1,25-dihydroxyvitamin D production and intestinal absorption of calcium in vivo. J Clin Invest. 1986 Aug; 78 (2): 456-61.
28. Kawashima H, Torikai S, Kurokawa K., Calcitonin selectively stimulates 25-hydroxyvitamin D3-1 alpha-hydroxylase in proximal straight tubule of rat kidney. Nature. 1981 May 28; 291 (5813): 327-9.
29. Chabardes D, Imbert-Teboul M, Montegut M, Clique A, Morel F., Distribution of calcitonin-sensitive adenylate cyclase activity along the rabbit kidney tubule. Proc Natl Acad Sci U S A. 1976 Oct; 73 (10): 3608-12.
30. Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel RF., Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest. 2002 Dec; 110 (12): 1849-57.
31. Huebner AK, Keller J, Catala-Lehnen P, Perkovic S, Streichert T, Emeson RB, Amling M, Schinke T., The role of calcitonin and alpha-calcitonin gene-related peptide in bone formation. Arch Biochem Biophys. 2008 May 15; 473 (2): 210-7.
32. Huebner AK, Schinke T, Priemel M, Schilling S, Schilling AF, Emeson RB, Rueger JM, Amling M., Calcitonin deficiency in mice progressively results in high bone turnover. J Bone Miner Res. 2006 Dec; 21 (12): 1924-34.
33. Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR., Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone. 2001 Aug; 29 (2): 162-8.
34. Cornish J, Callon KE, Lin CQ, Xiao CL, Gamble GD, Cooper GJ, Reid IR., Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J Bone Miner Res. 1999 Aug; 14 (8): 1302-9.
35. Brain SD, Grant AD., Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev. 2004 Jul; 84 (3): 903-34.
36. Schinke T, Liese S, Priemel M, Haberland M, Schilling AF, Catala-Lehnen P, Blicharski D, Rueger JM, Gagel RF, Emeson RB, Amling M., Decreased bone formation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J Bone Miner Res. 2004 Dec; 19 (12): 2049-56.
37. Ballica R, Valentijn K, Khachatryan A, Guerder S, Kapadia S, Gundberg C, Gilligan J, Flavell RA, Vignery A., Targeted expression of calcitonin gene-related peptide to osteoblasts increases bone density in mice. J Bone Miner Res. 1999 Jul; 14 (7): 1067-74.
38. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Gebre-Medhin S, Galson DL, Zajac JD, Karsenty G., Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol. 2004 Feb 16; 164 (4): 509-14.
39. Davey RA, Turner AG, McManus JF, Chiu WS, Tjahyono F, Moore AJ, Atkins GJ, Anderson PH, Ma C, Glatt V, MacLean HE, Vincent C, Bouxsein M, Morris HA, Findlay DM, Zajac JD., The calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J Bone Miner Res. 2008 Aug; 23 (8): 1182-93.
40. Schwenk F, Baron U, Rajewsky K., A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res. 1995 Dec 25; 23 (24): 5080-1.
41. Turner AG, Tjahyono F, Chiu WS, Skinner J, Sawyer R, Moore AJ, Morris HA, Findlay DM, Zajac JD, Davey RA., The role of the calcitonin receptor in protecting against induced hypercalcemia is mediated via its actions in osteoclasts to inhibit bone resorption. Bone. 2011 Feb 1; 48 (2): 354-61.
42. Chiu WS, McManus JF, Notini AJ, Cassady AI, Zajac JD, Davey RA., Transgenic mice that express Cre recombinase in osteoclasts. Genesis. 2004 Jul; 39 (3): 178-85.
43. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003 Dec 1; 22 (23): 6267-76.
44. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T., Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. The J Clin Invest. 1999 Nov; 104 (10): 1363-74.
45. Paic F, Igwe JC, Nori R, Kronenberg MS, Franceschetti T, Harrington P, Kuo L, Shin DG, Rowe DW, Harris SE, Kalajzic I., Identification of differentially expressed genes between osteoblasts and osteocytes. Bone. 2009 Oct; 45 (4): 682-92.
46. Gooi JH, Pompolo S, Karsdal MA, Kulkarni NH, Kalajzic I, McAhren SH, Han B, Onyia JE, Ho PW, Gillespie MT, Walsh NC, Chia LY, Quinn JM, Martin TJ, Sims NA., Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone. 2010 Jun; 46 (6): 1486-97.
47. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T., Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008; 3 (8): e2942.
48. Atkins GJ, Rowe PS, Lim HP, Welldon KJ, Ormsby R, Wijenayaka AR, Zelenchuk L, Evdokiou A, Findlay DM., Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res. 2011 Jul; 26 (7): 1425-36.
49. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ., Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011; 6 (10): e25900.
50. Martin TJ, Seeman E., Bone remodelling: its local regulation and the emergence of bone fragility. Best Pract Res Clin Endocrinol Metab. 2008 Oct; 22 (5): 701-22.
51. Chesnut CH 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L., Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res. 2005 Sep; 20 (9): 1548-61.
52. Qing H, Ardeshirpour L, Pajevic PD, Dusevich V, Jahn K, Kato S, Wysolmerski J, Bonewald LF., Demonstration of osteocytic perilacunar/canalicular remodeling in mice during lactation. J Bone Miner Res. 2012 May; 27 (5): 1018-29.
53. Zaidi M, Moonga BS, Abe E., Calcitonin and bone formation: a knockout full of surprises. J Clin Invest. 2002 Dec; 110 (12): 1769-71.
54. Baldock PA, Sainsbury A, Allison S, Lin EJ, Couzens M, Boey D, Enriquez R, During M, Herzog H, Gardiner EM., Hypothalamic control of bone formation: distinct actions of leptin and y2 receptor pathways. J Bone Miner Res. 2005 Oct; 20 (10): 1851-7.
55. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G., Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002 Nov 1; 111 (3): 305-17.
56. Kuestner RE, Elrod RD, Grant FJ, Hagen FS, Kuijper JL, Matthewes SL, O'Hara PJ, Sheppard PO, Stroop SD, Thompson DL., Cloning and characterization of an abundant subtype of the human calcitonin receptor. Mol Pharmacol. 1994 Aug; 46 (2): 246-55.
57. Sexton PM., Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol Neurobiol. 1991; 5 (2-4): 251-73.
58. Sheward WJ, Lutz EM, Harmar AJ., The expression of the calcitonin receptor gene in the brain and pituitary gland of the rat. Neurosci Lett. 1994 Nov 7; 181 (1-2): 31-4.
59. Netti C, Guidobono F, Sibilia V, Pagani F, Braga PC, Pecile A., Evidence of a central inhibition of growth hormone secretion by calcitonin gene-related peptide. Neuroendocrinology. 1989 Mar; 49 (3): 242-7.
60. Sibilia V, Netti C, Guidobono F, Villa I, Pecile A., Inhibitory effects of centrally administered/ASU1-7/eel calcitonin on basal and stimulated prolactin release in rats. J Endocrinol Invest. 1990 Jun; 13 (6): 507-11.
61. Tache Y, Garrick T, Raybould H., Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology. 1990 Feb; 98 (2): 517-28.
62. Wimalawansa SJ., Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol. 1997; 11 (2-3): 167-239.
63. Williams GA, Hargis GK, Galloway WB, Henderson WJ., Evidence for thyrocalcitonin in man. Proc Soc Exp Biol Med. 1966 Aug-Sep; 122 (4): 1273-6.
64. Hirsch PF, Munson PL., Thyrocalcitonin. Physiol Rev. 1969 Jul; 49 (3): 548-622.
65. Cooper CW, Hirsch PF, Toverud SU, Munson PL., An improved method for the biological assay of thyrocalcitonin. Endocrinology. 1967 Sep; 81 (3): 610-6.
66. Martin TJ, Melick RA., The acute effects of porcine calcitonin in man. Australas Ann Med. 1969 Aug; 18 (3): 258-63.
67. Parfitt AM., Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. Bone. 2003 Sep; 33 (3): 259-63.
68. Atkins GJ, Findlay DM., Osteocyte regulation of bone mineral: a little give and take. Osteoporos Int. 2012 Aug; 23 (8): 2067-79.
69. Hosking DJ, Gilson D., Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcaemia of malignancy. Q J Med. 1984; Summer; 53 (211): 359-68.
70. Kovacs CS., Calcium and bone metabolism during pregnancy and lactation. J Mammary Gland Biol Neoplasia. 2005 Apr; 10 (2): 105-18.
71. VanHouten JN, Dann P, Stewart AF, Watson CJ, Pollak M, Karaplis AC, Wysolmerski JJ., Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest. 2003 Nov; 112 (9): 1429-36.
72. Gonen E, Sahin I, Ozbek M, Kovalak E, Yologlu S, Ates Y., Effects of pregnancy and lactation on bone mineral density, and their relation to the serum calcium, phosphorus, calcitonin and parathyroid hormone levels in rats. J Endocrinol Invest. 2005 Apr; 28 (4): 322-6.
73. Stevenson JC, Hillyard CJ, MacIntyre I, Cooper H, Whitehead MI., A physiological role for calcitonin: protection of the maternal skeleton. Lancet. 1979 Oct 13; 2 (8146): 769-70.
74. Woodrow JP, Sharpe CJ, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS., Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology. 2006 Sep; 147 (9): 4010-21.
75. Miller S., Calcitonin-guardian of the Mammalian skeleton or is it just a fish story ? Endocrinology. 2006 Sep; 147 (9): 4007-9.
76. European Medicines Agency. Calcitonin [Internet]. London: European Medicines; Agency. 2012; [cited 2013 Jan 18]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/ Calcitonin/human-referral-000319.jsp&mid=WC0b01ac0580024e99.